ArticleMolecular biomedicine2025
Macrophage Trem2 deficiency aggravates aging-induced vascular remodeling by acting as a non-classical receptor of interleukin-13.
Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The TREM2 paradox in fibrosis: a unified mechanism for opposite outcomes across organs.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The receptor for triggering expressed on myeloid cells 2 (Trem2), which is a key hub of immune signals, is a cell-surface receptor expressed selectively in myeloid cells. Macrophages have multi-faceted functions in vascular aging. However, the function of Trem2 and its ligands in vascular aging has not been described. Here, we investigated Trem2's function in aging vasculature using transcriptome analysis, western blotting, and quantitative polymerase chain reaction (qPCR) to assess its expression. Aged (24-month-old) wild-type mice exhibited significantly upregulated Trem2 in aortic senescent macrophages compared to young (2-month-old) controls. Compared with littermate controls, aged mice with macrophage-specific Trem2 knockout (T2-cKO) developed exacerbated arterial stiffness, impaired vascular contractility, and an acceleration of histological aging markers. Trem2 deficiency intensified aortic inflammatory responses and oxidative stress. Mechanistically, interleukin (IL)-13 from senescent macrophages directly bound Trem2, activating the Syk-Sp1-SLC25A51 pathway to enhance mitochondrial nicotinamide adenine dinucleotide (NAD)⁺ transport. This triggered metabolic reprogramming, increasing alpha-ketoglutarate (α-KG) production, which modulated vascular smooth muscle cell (VSMC) phenotype. Notably, α-KG supplementation in vivo rescued Trem2 deficiency-driven vascular aging and dysfunction. Our study identifies the IL-13/Trem2 axis as a protective mechanism against vascular aging via α-KG-dependent metabolic crosstalk between macrophages and VSMCs. Thus, Trem2 may be a treatment target for diseases related to vascular aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.